Skip to search.
 FTSE 100 Down 0.28%

More On SUMM.L

Quotes

Derivatives

  • Warrants
  • Investment Products

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Summit Therapeutics plc (SUMM.L)

-LSE Ticker: N40HZ0/ISIN: GB00BN40HZ01
99.50 0.00(0.00%) 25 Aug 15:21
Prev Close:99.50
Open:99.50
Bid:N/A x 200000
Ask:N/A x 250000
1y Target Est:N/A
Beta:N/A
Next Earnings Date:N/A
Day's Range:97.00 - 98.44
52wk Range:82.66 - 159.75
Volume:18,332
Avg Vol (3m):30,132
Market Cap:61.18m
P/E (ttm):N/A
EPS (ttm):-0.31
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in GBp.

Headlines

  • No Headlines available for SUMM.L at this time.

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):5,551,459.64
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Jan-17) :-38.78
Quarterly EPS Est (0-00-31) :N/A
Mean Recommendation*:1.0
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to treat genetic and infectious diseases in the United Kingdom and North America. more
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback